



## Article

# The Polyextreme Ecosystem, Salar de Huasco at the Chilean Altiplano of the Atacama Desert Houses Diverse *Streptomyces* spp. with Promising Pharmaceutical Potentials

Carlos Cortés-Albayay <sup>1,2,3,4</sup>, Johanna Silber <sup>5</sup>, Johannes F. Imhoff <sup>5</sup> , Juan A. Asenjo <sup>3</sup>,  
Barbara Andrews <sup>3</sup>, Imen Nouioui <sup>4,\*</sup> and Cristina Dorador <sup>1,2,\*</sup> 

<sup>1</sup> Laboratory of Microbial Complexity and Functional Ecology, Centre for Biotechnology and Bioengineering-CeBiB, University of Antofagasta, Av. Angamos, Antofagasta 601, Chile; c.j.cortesbt@gmail.com

<sup>2</sup> Department of Biotechnology, Faculty of Marine Science and Biological Resources, University of Antofagasta, Av. Angamos, Antofagasta 601, Chile

<sup>3</sup> Centre for Biotechnology and Bioengineering—CeBiB, Department of Chemical Engineering and Biotechnology, University of Chile, Beauchef, Santiago 851, Chile; juasenjo@ing.uchile.cl (J.A.A.); bandrews@ing.uchile.cl (B.A.)

<sup>4</sup> School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK

<sup>5</sup> GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel, Düsternbrooker Weg 20, D-24105 Kiel, Germany; jsilber@geomar.de (J.S.); jimhoff@geomar.de (J.F.I.)

\* Correspondence: imen.nouioui@newcastle.ac.uk (I.N.); cristina.dorador@uantof.cl (C.D.)

Received: 18 February 2019; Accepted: 24 April 2019; Published: 28 April 2019



**Abstract:** Salar de Huasco at the Chilean Altiplano of the Atacama Desert is considered a polyextreme environment, where solar radiation, salinity and aridity are extremely high and occur simultaneously. In this study, a total of 76 bacterial isolates were discovered from soil samples collected at two different sites in the east shoreline of Salar de Huasco, including H0 (base camp next to freshwater stream in the north part) and H6 (saline soils in the south part). All isolated bacteria were preliminarily identified using some of their phenotypic and genotypic data into the genera *Streptomyces* (86%), *Nocardia* (9%), *Micromonospora* (3%), *Bacillus* (1%), and *Pseudomonas* (1%). *Streptomyces* was found dominantly in both sites (H0 = 19 isolates and H6 = 46 isolates), while the other genera were found only in site H0 (11 isolates). Based on the genotypic and phylogenetic analyses using the 16S rRNA gene sequences of all *Streptomyces* isolates, 18% (12 isolates) revealed <98.7% identity of the gene sequences compared to those in the publicly available databases and were determined as highly possibly novel species. Further studies suggested that many *Streptomyces* isolates possess the nonribosomal peptide synthetases-coding gene, and some of which could inhibit growth of at least two test microbes (i.e., Gram-positive and Gram-negative bacteria and fungi) and showed also the cytotoxicity against hepatocellular carcinoma and or mouse fibroblast cell lines. The antimicrobial activity and cytotoxicity of these *Streptomyces* isolates were highly dependent upon the nutrients used for their cultivation. Moreover, the HPLC-UV-MS profiles of metabolites produced by the selected *Streptomyces* isolates unveiled apparent differences when compared to the public database of existing natural products. With our findings, the polyextreme environments like Salar de Huasco are promising sources for exploring novel and valuable bacteria with pharmaceutical potentials.

**Keywords:** bioactive compounds; actinobacteria; Atacama; bioprospecting; Chilean Altiplano

## 1. Introduction

Actinomycetes are the most important bacteria that are capable of producing bioactive compounds. The majority of natural products for new pharmaceutical applications are derived from actinomycetes [1], while the notable member of actinomycetes, the genus *Streptomyces* is the major producer [2]. Many of these specialized metabolites biosynthesized by actinomycetes correspond to polyketides and nonribosomal peptides, which may act as antibiotics, immunosuppressants, anticancer/antitumor agents, toxins, and siderophores [3]. The members of the genus *Streptomyces* are widely distributed across various habitats and geographical locations [4]. *Streptomyces* produces spores that are characteristically resistant, allowing this bacterium to persist in the extreme environments and to maintain its viability for many years [5]. Previous studies showed that bacteria isolated from the extreme environments, such as the Mariana Trench [6], the polar and permafrost soils in the Arctic [7,8], and the extremely dry and saline soils of the Atacama Desert [9] are unique sources for the discovery of new bioactive compounds and many of them are possibly novel species [5,10,11].

The Atacama Desert is the driest place in the world located in South America, precisely in Chile, covering a 1000-km strip of land on the Pacific coast, west of the Andes Mountains. It is bordering Peru in the north and extending to the Copiapó River in the south. Nowadays, four novel *Streptomyces* species derive from this extreme desert, including *Streptomyces atacamensis* [12], *Streptomyces desertii* [13], *Streptomyces bulli* [14], and *Streptomyces leeuwenhoekii* [15]. *S. leeuwenhoekii* is the producer of two newly bioactive compounds comprised of (i) chaxamycins, showing antagonism against *Staphylococcus aureus* ATCC 25923, inhibiting the heat shock protein 90, and degrading proteins involved in cell proliferation [9] and (ii) chaxalactins, the anti-Gram-positive bacterial agents [16]. Two more novel compounds, atacamycins and chaxapeptin, each derive respectively from *Streptomyces* sp., C38 [17] and C58 [18] isolated from hyper-arid soil of the Laguna de Chaxa of Salar de Atacama in the north of Chile (a lagoon located in the commune of San Pedro de Atacama, province of El Loa). These two compounds are novel lasso-peptides produced by nonribosomal biosynthesis with post-translational modification and capable of inhibiting human lung cancer cell line A549. Another group of new compounds with antimicrobial activity, the abenquines A–D, was obtained from *Streptomyces* sp. DB634 isolated from the Salar de Tara in the Chilean Altiplano (>4000 m.a.s.l.) [19].


In Chile, the Chilean Altiplano of the Atacama Desert, is considered the highest plateau of the Andes Mountains (>3000 m.a.s.l.) with 14° to 22° S of latitude, in addition, it is subjected to strong climatic variation over different temporal scales [19]. This site offers a unique ecosystem with highly extreme conditions, such as changes in daily temperature from −10 to +25 °C [19] and it divides into different sites, for instance, Salar de Tara (at 150 km east of the town of San Pedro de Atacama, in the Province of El Loa, region Antofagasta) and Salar de Huasco (in the south of the town of Parinacota in the Arica and Parinacota regions). The Salar de Huasco is known by its polyextreme conditions, i.e., salinity gradient (from freshwater to saturation), elevated levels of solar radiation (<1100 W/m<sup>2</sup>), and negative water balance, which differs from the other locations previously studied in the Atacama Desert. Some areas of the Salar de Huasco have been found to house diverse microbes [20,21]. However, there is no study regarding the cultivable actinomycetes from this polyextreme ecosystem and their pharmaceutical potentials. Here, we aim to isolate bacteria with a focus on actinomycetes from different sites of the Salar de Huasco and to assess their pharmaceutical potentials in possession of nonribosomal peptide synthases (NRPS)-coding gene, antimicrobial activity, and cytotoxicity.

## 2. Materials and Methods

### 2.1. Isolation of Actinomycetes

Six soil samples were collected from sites H0 (base camp; freshwater stream) and H6 (saline soils) located in the northern and southern parts of the eastern shoreline of the Salar de Huasco, respectively [22] (Figure 1). Sites H0 and H6 were characterized as meso-saline and hyper saline sites with pH 7.6 and pH 8.6, respectively [23]. The samples were taken at 5 cm depth from the ground

surface using sterile polypropylene tubes and transferred to the laboratory. These samples were stored at ambient temperature for a period not exceeding 5 days. One g of soil sample was suspended in 9 mL of  $\frac{1}{4}$  strength Ringer's solution, and 1 mL of the soil suspension was diluted 100-fold and mixed in an orbital shaker at 150 rpm for 1 h. The diluted soil suspension was pretreated by heating at 55 °C for 6 min in a thermo-regulated bath [4]. The heated aliquot (0.1 mL) was spread over the surface of starch casein agar medium (SCA), supplemented with 50 µg/mL nystatin and 50 µg/mL cycloheximide to prevent fungal contamination [24]. All seeded agar plates were prepared in triplicate and incubated at 28 °C for 14–21 days [25]. Colonies with rough appearance, powdery or tough texture and branching filaments with and without aerial mycelia were subcultured on SCA plates and incubated at 28 °C for 14 days. A subculture of each isolate was prepared on International *Streptomyces* Project III (ISP3) medium [26] under the same condition cited above. The purity of the each isolates was checked using light microscope.



**Figure 1.** 1: Satellite image of Salar de Huasco indicating sampling sites. Image Google Earth V 7.3.2.5776. (3 March 2019). Salar de Huasco, Chile. 20°16'22.68'' S, 68°52'54.08' W, Eye alt 14.35 mi. CNES/Airbus 2019 [30 March 2019]. <https://earth.google.com/web/@-20.29749527,-68.84083051,3780.51679815a,17347.67437889d,35y,360h,0t,0r>. 2: Sampling sites at Salar de Huasco, Northern Chile. (A) Panoramic view of Salar de Huasco, Chilean Altiplano; (B) Site H0, saline crusts; (C) Site H6, soils; (D) Site H6, saline soils.

## 2.2. Identification of Bacterial Isolates

### 2.2.1. Morphological Characterization Based on Color Grouping

The morphological characteristics of all bacterial isolates grown on ISP3 medium, such as aerial spore mass color, pigmentation of vegetative or substrate mycelium, and the production of diffusible pigment were examined. The color of the aerial and substrate mycelium of the isolates were described referring to the National Bureau of Standards (NBS) Color Name Charts [27]. Each isolate was maintained on glucose yeast extract and malt extract (GYM) medium and stored as spore suspensions and hyphae in 25% (*v/v*) glycerol at −80 °C.

### 2.2.2. 16S rRNA Gene-Based Phylogenetic Analysis

Bacterial cultures were prepared in tryptone yeast extract (ISP1) broth at 28 °C for 7 days, in which 2 mL was transferred to vials containing 0.5 mm glass beads (BioSpec Products Inc, Bartlesville, OK, USA) to breakdown mechanically the bacterial cells (Mini Bead Beater, Bead Homogenizer, BioSpec Products Inc, Bartlesville, OK, USA). Total genomic DNA was extracted from the homogenized bacterial suspension using the AxyPrep Bacterial Genomic DNA Miniprep kit (Axygen Biosciences, Union City, NJ, USA) as recommended by the manufacturer.

The 16S rRNA gene was amplified by PCR using the universal primers for bacteria, Eub9-27F and Eub1542R [28]. Every reaction was performed in a final volume of 50 µL, containing 50–100 ng of genomic DNA, 2.0 µM of each primer, 19 µL of nuclease-free MilliQ-H<sub>2</sub>O (Merck Millipore, Burlington, MA, USA), and 25 µL of SapphireAmp® Fast PCR Master Mix (TaKaRa, Japan). PCR was carried out in a thermocycler under the following conditions: Initial denaturation at 94 °C for 5 min, 30 cycles of denaturation at 94 °C for 45 s, annealing at 54 °C for 45 s, and extension at 72 °C for 1.5 min, and a final extension at 72 °C for 5 min. The PCR (Polymerase Chain Reaction) products were checked by 1% (*w/v*) agarose gel electrophoresis and subsequently sequenced by capillary sequencing using an ABI Prism 3730XL automated DNA sequencer (Applied Biosystems, MacroGen Inc., Seoul, Korea).

The 16S rRNA gene sequences were analyzed and edited using the software DNA Baser Sequence Assembler version 3.5 (Heracle BioSoft SRL, 2014). The partial 16S rRNA gene sequences of the isolates were aligned using RDP II [29]. EzTaxon [30] was used to retrieve the nearest phylogenetic neighbors of all bacterial isolates. The nearly completed 16S rRNA gene sequences (>1300 nt) of the isolates were deposited in the GenBank database with the accession numbers KX130868-KX130886.

The phylogenetic tree was constructed using Neighbor-Joining algorithms [31] with a Tamura-Nei substitution model using MEGA 7.0 software [32]. The multiple alignments of all the 16S rRNA gene sequences were performed using MUSCLE (Multiple Sequence Comparison by Log- Expectation) algorithm [33]. The robustness of the tree was evaluated using 1000 Bootstrap [34].

### 2.3. Evaluations of Pharmaceutical Potentials

#### 2.3.1. Genotyping of Nonribosomal Peptide Synthetase (NRPS)

*Streptomyces* isolates with nearly complete 16S rRNA gene sequences were screened for the presence of nonribosomal peptide synthetase (NRPS) domains using the primers A3F (5'-GCSTACSYSATS TACACSTCSGG-3') and A7R (5'-SASGTCVCCSGTSCGGTAS-3') following a method described by Ayuso-Sacido and Genilloud [35].

#### 2.3.2. Preparation of Crude Extracts and Bioactivity Assessments

The secondary metabolites were extracted from *Streptomyces* isolates possessing NRPS domains following a protocol described by Schneemann et al. [36] with some modifications. Each isolate was grown in 100 mL of GYM (pH 7.2), and in starch-soy peptone (SPM, pH 7.0) liquid media supplemented with 2% NaCl and incubated at 28 °C for one week, with shaking at 135 rpm, in an orbital shaking incubator (MaxQ 4000, Thermo Fisher Scientific, Waltham, MA, USA). Extraction of metabolites from the whole culture broths started with the addition of 150 mL of ethyl acetate to each flask, followed by stirring and sonication cycles and kept at 4 °C overnight for effective phase separation. The lower aqueous phase was discarded, and the ethyl acetate phase (supernatant) was dried in a rotary evaporator (Büchi, Flawil, Switzerland) at ambient temperature.

The antimicrobial activity of the crude extracts was evaluated by bioassays using stocks solutions with a concentration of 1% *w/v* (equivalent to 10 mg/mL in methanol). The bioassays of antibacterial and antifungal activities were performed following a procedure described by Schneemann et al. [36]. Aliquot of 5 µL of each crude extract was added in each well of the 96-well microtiter plate and then the solvent was evaporated using vacuum centrifuge (Biotage SPE Dry, Uppsala, Sweden) before append 195 µL of the test microbial suspension. The final concentration of each crude extract in the bioassays was 250 µg/mL. The test organisms comprised of gram-positive bacteria: *Staphylococcus epidermidis* DSM 20044<sup>T</sup>, methicillin-resistant *Staphylococcus aureus* DSM 18827, *Pseudomonas aeruginosa* DSM 50071<sup>T</sup>, and *Propionibacterium acnes* DSM 1897<sup>T</sup>, gram-negative bacteria: *Xanthomonas campestris* DSM 2405 and *Erwinia amylovora* DSM 50901, and fungi: *Candida albicans* DSM 1386, *Trichophyton rubrum*, *Septoria tritici*, and *Phytophthora infestans*. *Trichophyton rubrum* was obtained from F. Horter (Department of Dermatology, Allergology, and Venerology, University Hospital Schleswig-Holstein, Kiel, Germany while *Septoria tritici* and *Phytophthora infestans* were obtained from Dr. J. B. Speakman



(BASF, Ludwigshafen, Germany). The positive control for the test bacteria was 100 µg/well of chloramphenicol and that for the test fungi was 200 µg/well of cycloheximide, while the negative control was no compound applied.

The cytotoxicity test was performed following a method described by Schulz et al. [19]. Aliquot (1 µL) of each crude extract was added in a final assay volume of 100 µL of the mouse fibroblasts (NIH-3T3) and hepatocellular carcinoma (HepG2 ACC 180) cell lines. NIH-3T3 cell line was provided by G. Rimbach, University of Kiel, Germany while HepG2 ACC 180 was obtained from Leibniz Institute DSMZ-German collection of microorganisms and cell cultures, Braunschweig, Germany. The final concentration of each crude extract in the bioassays was 100 µg/mL. The positive control for these assays was tamoxifen with a final concentration of 40 µM. No compound was added for the negative control.

### 2.3.3. Profiling of Metabolites in Crude Extracts

The crude extracts dissolved in methanol were elucidated by analytical reversed-phase HPLC-UV-MS (High-Performance Liquid Chromatography with UV detector coupled to Mass Spectrometry), in a VWR-Hitachi La-Chrom Elite System, coupled to a diode array detector and a Phenomenex Onyx Monolithic column (C18, 100 × 3.00 mm) according to the conditions described by Silber et al. [37]. For the mass detection, the HPLC system was coupled to an ion trap detector (Esquire4000, Bruker Daltonics, Billerica, MA, USA). The UV-Vis spectra of peaks obtained from each bacterial crude extract were compared with the Dictionary of Natural Products 2012 [38].

## 3. Results and Discussion

### 3.1. Selective Isolation and Identification of the Isolates

A number of 30 and 46 isolates were obtained from soils samples of sites H0 and H6, respectively. These isolates were obtained from plates with 10 fold dilutions, and 97% (74 isolates) of them were found to be affiliated with the phylum *Actinobacteria* based on the 16S rRNA gene sequence similarity. Two isolates were classified as *Bacillus* and *Pseudomonas*, while the others belong to *Nocardiopsis* (7 isolates), *Micromonospora* (2 isolates), and *Streptomyces* (65 isolates) (Table 1).

**Table 1.** 16S rRNA gene-based identification of all bacteria isolated from Salar de Huasco.

Class	Family	Genus	Number of Isolate (%)	Site of Isolation
<i>Actinobacteria</i>	<i>Streptomycetaceae</i>	<i>Streptomyces</i>	65 (86%)	H0 and H6
	<i>Nocardiopsaceae</i>	<i>Nocardiopsis</i>	7 (9%)	H0
	<i>Micromonosporaceae</i>	<i>Micromonospora</i>	2 (3%)	H0
<i>Bacilli</i>	<i>Bacillaceae</i>	<i>Bacillus</i>	1 (1%)	H0
<i>Gammaproteobacteria</i>	<i>Pseudomonadaceae</i>	<i>Pseudomonas</i>	1 (1%)	H0


The eleven non-*Streptomyces* isolates were found only in the soil sample with neutral pH 7.6 collected from site H0, while the majority of the *Streptomyces* isolates (40) were obtained from the hypersaline site H6 with pH 8.6. All 65 *Streptomyces* isolates were subdivided into three color grouping after incubation on ISP3 agar medium at 28 °C for 14 days (Table 2). They showed the typical morphology of the genus *Streptomyces* in formation of aerial mycelium and spore chains. Most of these isolates produced diffusible pigments and excreted colored aqueous droplets on the hydrophobic surface of their colonies.

**Table 2.** Morphological and molecular characteristics of some *Streptomyces* spp. <sup>a</sup> isolated from Salar de Huasco.

Isolate Code	Site of Isolation	Morphological Characteristics <sup>b</sup>			Molecular Characteristics			
		Aerial Spore Mass	Substrate Mycelium	Diffusible Pigments	Closest Type Strain	16 rRNA Gene Accession Number	Similarity (%)	NRPS (Adenylation Domain)
HST05	H6	White	Light yellowish pink	-	<i>Streptomyces canus</i> DSM 40017 <sup>T</sup>	KQ948708	96.8	+
HST09	H6	Dark greyish blue	Deep purplish red	-	<i>Streptomyces lienomycinii</i> LMG 20091 <sup>T</sup>	AJ781353	99.6	+
HST14	H6	White	Pale violet	Light greyish brown	<i>Streptomyces atroolivaceus</i> NRRL ISP-5137 <sup>T</sup>	JNXG01000049	96.0	-
HST18	H6	-	Dark olive green	Moderate yellow green	<i>Streptomyces alboniger</i> NRRL B-1832 <sup>T</sup>	LIQN01000245	96.7	+
HST19	H6	Dark greyish blue	Dark greenish yellowish green	Dark greyish yellowish brown	<i>Streptomyces collinus</i> NBRC 12759 <sup>T</sup>	AB184123	99.2	+
HST21	H6	White	Greyish yellow	Moderate olive brown	<i>Streptomyces albidochromogenes</i> NBRC 101003 <sup>T</sup>	AB249953	99.1	+
HST22	H6	White	Deep orange yellow	Moderate olive brown	<i>Streptomyces albidochromogenes</i> NBRC 101003 <sup>T</sup>	AB249953	99.0	+
HST23	H6	Light pink	Light orange yellow	Dark yellow	<i>Streptomyces purpureus</i> NBRC 13927 <sup>T</sup>	AB184547	98.8	-
HST28	H6	White	Light olive brown	Dark brown	<i>Streptomyces kanamyceticus</i> NBRC 13414 <sup>T</sup>	AB184388	98.8	+
HST50	H6	White	Greyish reddish brown	-	<i>Streptomyces ambofaciens</i> ATCC 23877 <sup>T</sup>	CP012382	96.0	-
HST51	H6	Light pink	Strong yellowish brown	-	<i>Streptomyces alboniger</i> NRRL B-1832 <sup>T</sup>	LIQN01000245	98.6	+
HST54	H6	White	Deep red	Light greyish brown	<i>Streptomyces griseolus</i> NRRL B-2925 <sup>T</sup>	JOFC01000069	97.6	-
HST61	H6	Pale yellowish pink	Pale orange yellow	-	<i>Streptomyces kanasensis</i> ZX01 <sup>T</sup>	JN572690	99.6	-
HST66	H6	White	Deep greenish yellow	-	<i>Streptomyces fumanus</i> NBRC 13042 <sup>T</sup>	AB184273	96.9	+
HST68	H6	Greyish blue	Pinkish grey	-	<i>Streptomyces ambofaciens</i> ATCC 23877 <sup>T</sup>	CP012382	96.0	+
HST69	H0	White	Brilliant yellow	-	<i>Streptomyces chlorus</i> BK125 <sup>T</sup>	LIQN01000245	98.1	+
HST72	H0	White	Strong yellowish brown	Strong brown	<i>Streptomyces microflavus</i> NBRC 13062 <sup>T</sup>	AB184284	97.9	-
HST82	H0	White	Pale yellowish pink	-	<i>Streptomyces cyaneofuscatus</i> NRRL B-2570 <sup>T</sup>	JOEM01000050	95.6	-
HST83	H0	White	Strong yellowish brown	Strong brown	<i>Streptomyces pratensis</i> ch24 <sup>T</sup>	JQ806215	97.8	+

<sup>a</sup> These *Streptomyces* isolates were selected based on the quality of their 16S rRNA gene sequences (>1300 nt). <sup>b</sup> The morphological characteristics were observed after growing *Streptomyces* isolates on ISP3 agar medium at 28 °C for 14 days.

Nineteen out of 65 *Streptomyces* isolates were selected for further study based on their nearly complete 16S rRNA gene sequences (>1300 bp). These 19 isolates widely distributed across the phylogenetic tree of the genus *Streptomyces* supported by high bootstrap values as shown in Figure 2. A total of 12 isolates showed a 16S rRNA gene sequence similarity below the 98.7% threshold for proposing as novel species [39] (Table 2), while the other seven (HST09, HST19, HST21, HST22, HST23, HST28, and HST61) found to occupy distinct phylogenetic positions from their closest relatives with no close relationship with any species and type strains of the genus *Streptomyces* from the Atacama Desert described so far [11–15] (Figure 2).



**Figure 2.** Neighbor-joining phylogenetic tree based on almost complete 16S RNA sequences (>1300 nt) of the 19 *Streptomyces* isolates derived from Salar de Huasco and their closely related species. The tree was constructed using the Neighbor-Joining algorithm and the Jukes–Cantor substitution model. The scale bar indicates 0.005 substitutions per nucleotide, and *Streptomyces albus* subsp. *albus* DSM 40313<sup>T</sup> was used as an out-group. Bootstrap values above 50% are present.

Isolate HST19 forms a distinct branch closely related to the type strain of *Streptomyces collinus* NBRC 12759<sup>T</sup> (99.2%) [40], *Streptomyces iakyrus* NRRL ISP-5482<sup>T</sup> (98.8%) [41], and *Streptomyces violaceochromogenes* NBRC 13100<sup>T</sup> (99.3%) [42]. Isolates HST21 and HST22 form a well-supported sub-clade closely associated to *Streptomyces albidochromogenes* NBRC 101003<sup>T</sup> (99.0%) [43]. Strain HST61 occupied a phylogenetic position close to “*Streptomyces kanasensis*” ZX01 (99.6%) which is a producer of a novel antiviral glycoprotein [44]. Isolate HST28 showed close phylogenetic relationship with *Streptomyces kanamyceticus* NBRC 13414<sup>T</sup> (98.8%) [45], while isolate HST23 had close relatedness to *Streptomyces purpureus* NBRC 13927<sup>T</sup> (98.8%) [46]. Isolates HST09 occupied distant subclade closely related to *Streptomyces lienomycini* LMG 20091<sup>T</sup> (99.6%) [43].

The length of the branch of all *Streptomyces* isolates in the phylogenetic tree and the assignment to these isolates to completely different clades from each other, except for isolates HST21 and HST22, highlight the divergence of them from their closely related neighbors. Further studies need to be performed to confirm the right affiliations of these isolates to the novel species within the evolutionary radiation of the genus *Streptomyces*.

Most isolates (except for isolates HST83, HST72, HST21, and HST22) showed divergent phylogenetic positions compared to the type species of the genus *Streptomyces* (Figure 2). Therefore, these strains should be designed for further taxonomic and analytical chemistry analyses to confirm their novelty at species rank and as a source of novel chemical entities (Table 3).

**Table 3.** Bioactivities of crude extracts derived from *Streptomyces* spp. of Salar de Huasco.

Crude Extract Derived From <i>Streptomyces</i> Isolate Grown in Different Media	Growth Inhibition (%) <sup>a</sup>										
	Antibacterial Activity					Antifungal Activity				Cytotoxicity	
	Gram-Positive Bacteria		Gram-Negative Bacteria								
	Se	MRSA	Pa	Xc	Ea	Ca	Tru	Sep	PhA	NIH-3T3	HepG2
HST09-GYM	96	92	-	27	-	-	72	-	-	99	79
HST09-SPM	28	28	-	-	-	-	-	-	-	36	-
HST14-GYM	-	-	-	-	-	-	33	-	-	50	40
HST14-SPM	-	-	-	-	-	-	30	-	-	51	42
HST19-GYM	-	-	57	55	-	-	58	-	-	57	34
HST19-SPM	61	60	53	76	-	-	-	-	-	20	-
HST21-GYM	99	98	-	84	91	-	86	22	50	99	99
HST21-SPM	97	95	-	79	96	-	100	-	53	99	99
HST23-GYM	93	92	100	97	71	77	100	100	49	99	99
HST23-SPM	98	97	97	99	97	76	100	100	49	99	99
HST28-GYM	97	98	100	100	22	45	37	94	27	100	100
HST28-SPM	100	100	100	100	-	39	29	89	25	97	100
HST50-GYM	96	-	90	97	92	-	41	29	-	43	38
HST50-SPM	93	41	97	98	-	-	57	30	-	-	-
HST54-GYM	96	95	96	78	-	-	48	-	39	53	24
HST54-SPM	95	92	93	71	-	-	47	-	35	52	25
HST61-GYM	73	-	-	76	63	-	59	59	22	-	-
HST61-SPM	81	41	-	62	68	-	43	62	26	-	-
HST68-GYM	93	-	90	97	91	-	30	21	-	-	21
HST68-SPM	38	-	50	24	-	-	45	-	-	-	-
HST72-GYM	95	97	98	35	-	28	60	100	47	97	69
HST72-SPM	97	97	99	56	-	-	50	96	28	86	59
HST82-GYM	100	97	90	92	-	-	41	-	-	50	40
HST82-SPM	-	47	-	-	-	-	26	-	-	39	38

<sup>a</sup> The average results derived from triplicate assays are shown with inhibition percentage (%) of growth of Se (*Staphylococcus epidermis*), MRSA (methicillin-resistant *Staphylococcus aureus*), Pa (*Propionibacterium acnes*), Xc (*Xanthomonas campestris*), Ea (*Erwinia amylovora*), Ca (*Candida albicans*), Tru (*Trichophyton rubrum*), Sep (*Septoria tritici*), Pha (*Phytophthora infestans*), NIH-3T3 (mouse fibroblasts), and HepG2 (hepatocellular carcinoma). GYM and SPM refer respectively to glucose yeast extract plus malt extract medium and starch-soy peptone medium, in which the *Streptomyces* isolates were grown before the preparation of their crude extracts. The negative results are shown with (-).



### 3.2. Secondary Metabolite Analysis

The NRPSs are multimodular enzymatic complexes constituted by three main catalytic domains: The adenylation (A) domain, responsible for the recognition and activation of a specific amino acid, the condensation (C) domain catalyses the formation of the peptidic bond (C-N) between different modules, and the peptidyl-carrier (T) domain which transfers the activated amino acids from the A domain to the C domain of the same module [6]. The presence of A domain in actinobacterial genomes reflects the biosynthesis of secondary metabolites. The products of the NRPS biosynthetic pathway are diverse secondary metabolites including several antitumor compounds [47,48]. A total of 12 *Streptomyces* isolates (63%) (Table 2) revealed the possession of NRPS A domain. A correlation has been previously observed between the numbers of isolates with the positive NRPS-PCR reaction and the production of bioactive compounds [36]. The 12 NRPS-holding isolates were tested further for their bioactivities. Isolates HST05, HST14, HST18 and HST51 were discarded from this analysis due to their low growth rate on the test media. From the pairs of isolates HST83-HST72 and HST21-HST22 that occupied the same phylogenetic position (Figure 2), we only included isolates HST21 and HST72 for the bioactivity tests.

The crude extracts obtained from *Streptomyces* isolates grown previously in GYM or SPM broth demonstrated the different HPLC profiles (Figure S1). These isolates have a wide range of metabolites in their chromatograms (Figure S1). The UV-Vis and MS data of the crude extracts in comparison with the Dictionary of Natural Products Database exhibited a low similarity to the known compounds, which highlights the novelty of these natural entities. The majority of the isolates showed high antifungal, antibacterial and cytotoxic activities (Table 3), supported by the high levels of growth inhibition (>90%) against several pathogens, such as, MRSA (HST09, HST21, HST23, HST28, HST72, HST82, HST50, HST54, and HST68), *P. acnes* (HST23, HST23, HST28, HST50, HST54, and HST72), *X. campestris* (HST23, HST28, HST50, and HST68), and *Trichophyton rubrum* (HST21 and HST23). The crude extracts at a final extract concentration of 100 µg/mL from isolates HST09, HST21, HST23, HST28, HST66, and HST72 also showed the high levels of cytotoxicity (~99%) against the tumor cell lines of HepG2 and NIH-3T3. Based on the overall bioactivities, isolates HST21, HST23, and HST28 were the producers of broad-spectrum antibiotics. These results are coherent with those described *Streptomyces* spp. isolated from the other Salar sites of the Atacama Desert, e.g., *Streptomyces* sp. C38 from Salar de Atacama that produces atacamycins A–C [17] and *Streptomyces* sp. DB634 from Salar de Tara that produces abenquines A–D [19].

The polyextreme ecosystem of Salar de Huasco forces the microorganisms to adapt to it [49], which led to the development of unique *Streptomyces* taxa that are clearly different from the other sites in the Atacama Desert and the Altiplano [9] and probably vary due to the spatial heterogeneity within the same area [50].

## 4. Conclusions

*Streptomyces* spp. isolated from the Salar de Huasco at the Chilean Altiplano showed taxonomic divergences from the species with validly published names and capabilities to produce novel secondary metabolites with interesting pharmaceutical potentials. These findings open up the prospect for novel drug discovery. Further analytical and chemical analyses should be carried out to elucidate these microbial products in order to be exploited for future biotechnological applications.

**Supplementary Materials:** The following are available online at <http://www.mdpi.com/1424-2818/11/5/69/s1>, Figure S1: HPLC-UV/Vis Chromatographic profiles of extracts obtained from culture metabolic extracts for analyzed strains, which were grown in liquid media GYM (A) and SPM (B) both of them at 2% NaCl.

**Author Contributions:** C.C.-A. carried out the experiments, analyzed the data and wrote the manuscript with support from I.N., C.D., J.A.A. and B.A. I.N. contributed to the interpretation of the results and helped in writing the manuscript. C.D. designed the experiments and supervised the work. J.S. and J.F.I. performed the bioassays tests and the mass spectrometry analyses. All the authors discussed the results and contributed to the final version of the manuscript.

**Funding:** This study was supported by grants from DAAD-CONICYT Project 698, FONDECYT 1110953; 1140179 and by CONICYT with the PFCHA/DOCTORADO BECAS CHILE/2016—21160585 and the Basal Centre Grant for CeBiB (FB0001).

**Acknowledgments:** We acknowledge to Jaime Guerrero for his help in the field, Pablo Aguilar for sampling support, Diego Cornejo for technical support and the whole team of the Laboratory of Functional Ecology and Microbial Complexity of Antofagasta Institute, University of Antofagasta (Antofagasta, Chile).

**Conflicts of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Bérdy, J. Bioactive microbial metabolites. *J. Antibiot.* **2005**, *58*, 1–26. [\[CrossRef\]](#)
2. Watve, M.; Tickoo, R.; Jog, M.; Bhole, B. How many antibiotics are produced by the genus *Streptomyces*? *Arch. Microbiol.* **2001**, *176*, 386–390. [\[CrossRef\]](#)
3. Amoutzias, G.D.; Anargyros Chaliotis, A.; Mossialos, D. Discovery Strategies of Bioactive Compounds Synthesized by Nonribosomal Peptide Synthetases and Type-I Polyketide Synthases Derived from Marine Microbiomes. *Mar. Drugs* **2016**, *14*, 80. [\[CrossRef\]](#)
4. Antony-Babu, S.; Goodfellow, M. Biosystematics of alkaliphilic *Streptomyces* isolated from seven locations across a beach and dune sand system. *Antonie Leeuwenhoek* **2008**, *94*, 581–591. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Bull, A.T.; Stach, J.E.; Ward, A.C.; Goodfellow, M. Marine actinobacteria: Perspectives, challenges, future directions. *Antonie Leeuwenhoek* **2005**, *87*, 65–79. [\[CrossRef\]](#)
6. Pathom-aree, W.; Stach, J.E.M.; Ward, A.C.; Horikoshi, K.; Bull, A.T.; Goodfellow, M. Diversity of Actinomycetes isolated from Challenger Deep sediment (10,898 m) from the Mariana Trench. *Extremophiles* **2006**, *10*, 181–189. [\[CrossRef\]](#)
7. Lyutskanova, D.; Ivanova, V.; Stoilova-Disheva, M.; Kolarova, M.; Aleksieva, K.; Peltekova, V. Isolation and characterization of a psychrotolerant *Streptomyces* strain from permafrost soil in Spitsbergen, producing phthalic acid ester. *Biotechnol. Biotechnol. Equip.* **2009**, *23*, 1220–1224. [\[CrossRef\]](#)
8. Steven, B.; Pollard, W.H.; Greer, C.W.; Whyte, L.G. Microbial diversity and activity through a permafrost/ground ice core profile from the Canadian high Arctic. *Environ. Microbiol.* **2008**, *10*, 3388–3403. [\[CrossRef\]](#)
9. Okoro, C.K.; Asenjo, J.A.; Andrews, B.A.; Ferguson, G.; Bull, A.T.; Goodfellow, M.; Ebel, R.; Jaspars, M. Chaxamycins A–D, bioactive ansamycins from a hyper-arid desert *Streptomyces* sp. *J. Nat. Prod.* **2011**, *74*, 1491–1499. [\[CrossRef\]](#)
10. Fiedler, H.P.; Bruntner, C.; Bull, A.T.; Ward, A.C.; Goodfellow, M.; Potterat, O.; Puder, C.; Mihm, G. Marine Actinomycetes as a source of novel secondary metabolites. *Antonie Leeuwenhoek* **2005**, *87*, 37–42. [\[CrossRef\]](#)
11. Goodfellow, M.; Nouiou, I.; Sanderson, R.; Xie, F.; Bull, A.T. Rare taxa and dark microbial matter: Novel bioactive actinobacteria abound in Atacama Desert soils. *Antonie Leeuwenhoek* **2018**, *111*, 1315–1332. [\[CrossRef\]](#)
12. Santhanam, R.; Okoro, C.K.; Rong, X.; Huang, Y.; Bull, A.T.; Weon, H.Y.; Andrews, B.A.; Asenjo, J.A.; Goodfellow, M. *Streptomyces atacamensis* sp. nov., isolated from an extreme hyper-arid soil of the Atacama Desert, Chile. *Int. J. Syst. Evol. Microbiol.* **2012**, *62*, 2680–2684. [\[CrossRef\]](#)
13. Santhanam, R.; Okoro, C.K.; Rong, X.; Huang, Y.; Bull, A.T.; Andrews, B.A.; Asenjo, J.A.; Weon, H.Y.; Goodfellow, M. *Streptomyces deserti* sp. nov., isolated from hyper-arid Atacama Desert soil. *Antonie Leeuwenhoek* **2012**, *101*, 575–581. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Santhanam, R.; Rong, X.; Huang, Y.; Andrews, B.A.; Asenjo, J.A.; Goodfellow, M. *Streptomyces bullii* sp. nov., isolated from a hyper-arid Atacama Desert soil. *Antonie Leeuwenhoek* **2013**, *103*, 367–373. [\[CrossRef\]](#)
15. Busarakam, K.; Bull, A.T.; Girard, G.; Labeda, D.P.; Van Wezel, G.P.; Goodfellow, M. *Streptomyces leeuwenhoekii* sp. nov., the producer of chaxalactins and chaxamycins, forms a distinct branch in *Streptomyces* gene trees. *Antonie Leeuwenhoek* **2014**, *105*, 849–861. [\[CrossRef\]](#)
16. Rateb, M.E.; Houssen, W.E.; Harrison, W.T.A.; Deng, H.; Okoro, C.K.; Asenjo, J.A.; Andrews, B.A.; Bull, A.T.; Goodfellow, M.; Ebel, R.; et al. Diverse metabolic profiles of a *Streptomyces* strain isolated from a hyper-arid environment. *J. Nat. Prod.* **2011**, *74*, 1965–1971. [\[CrossRef\]](#)
17. Nachtigall, J.; Kulik, A.; Helaly, S.; Bull, A.T.; Goodfellow, M.; Asenjo, J.A.; Maier, A.; Wiese, J.; Imhoff, J.F.; Sussmuth, R.D.; et al. Atacamycins A–C, 22-membered antitumor macrolactones produced by *Streptomyces* sp. C38. *J. Antibiot.* **2011**, *64*, 775–780. [\[CrossRef\]](#)

18. Elsayed, S.S.; Trusch, F.; Deng, H.; Raab, A.; Prokes, I.; Busarakam, K.; Asenjo, J.A.; Andrews, B.A.; Van West, P.; Bull, A.T.; et al. Chaxapeptin, a lasso peptide from extremotolerant *Streptomyces leeuwenhoekii* strain C58 from the hyperarid Atacama Desert. *J. Org. Chem.* **2015**, *80*, 10252–10260. [[CrossRef](#)] [[PubMed](#)]
19. Schulz, D.; Beese, P.; Ohlendorf, B.; Erhard, A.; Zinecker, H.; Dorador, C.; Imhoff, J.F. Abenquines A–D: Aminoquinone derivatives produced by *Streptomyces* sp. strain DB634. *J. Antibiot.* **2011**, *64*, 763–768. [[CrossRef](#)] [[PubMed](#)]
20. Dorador, C.; Vila, I.; Witzel, K.-P.; Imhoff, J.F. Bacterial and archaeal diversity in high altitude wetlands of the Chilean Altiplano. *Fundam. Appl. Limnol.* **2013**, *182*, 135–159. [[CrossRef](#)]
21. Molina, V.; Hernandez, K.; Dorador, C.; Hengst, M.; Pérez, V. Bacterial active community cycling in response to solar radiation and their influence on nutrient changes in a high-altitude wetland. *Front. Microbiol.* **2016**, *7*, 1823. [[CrossRef](#)]
22. Dorador, C.; Vila, I.; Remonsellez, F.; Imhoff, J.F.; Witzel, K.-P. Unique clusters of Archaea in Salar de Huasco, an athalassohaline evaporitic basin of the Chilean Altiplano. *FEMS Microbiol. Ecol.* **2010**, *73*, 291–302. [[CrossRef](#)]
23. Dorador, C.; Meneses, D.; Urtuvia, V.; Demergasso, C.; Vila, I.; Witzel, K.P.; Imhoff, J.F. Diversity of Bacteroidetes in high-altitude saline evaporitic basins in northern Chile. *J. Geophys. Res.* **2009**, *114*, G00D05. [[CrossRef](#)]
24. Kuester, E.; Williams, S.T. Selection of media for isolation of *Streptomyces*. *Nature* **1964**, *202*, 928–929. [[CrossRef](#)]
25. Vickers, J.C.; Williams, S.T.; Ross, G.W. A taxonomic approach to selective isolation of *Streptomyces* from soil. In *Biological and Biochemical Aspects of Actinomycetes*; Ortiz-Ortiz, L., Bojalil, L.F., Yakoleff, V., Eds.; Academic Press: Orlando, FL, USA, 1984; pp. 553–561.
26. Shirling, E.B.; Gottlieb, D. Methods for characterization of *Streptomyces* species. *Int. J. Syst. Bacteriol.* **1966**, *16*, 313–340. [[CrossRef](#)]
27. Kelly, K.L. *Color Name Charts Illustrated with Centroid Colors*; Supplement to NBS Circular 553. Inter-Society Color Council—National Bureau of Standards (ISCC-NBS); U. S. National Bureau of Standards: Washington, DC, USA, 1964.
28. Stackebrandt, E.; Liesack, W. Nucleic Acids and Classification. In *Handbook of New Bacterial Systematics*; Goodfellow, M., O'Donnell, A.G., Eds.; Academic Press: London, UK, 1993; pp. 151–194.
29. Wang, Q.; Garrity, G.M.; Tiedje, J.M. Cole JR (2007) Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl. Environ. Microbiol.* **1984**, *73*, 5261–5267. [[CrossRef](#)] [[PubMed](#)]
30. Kim, O.S.; Cho, Y.J.; Lee, K.; Yoon, S.H.; Kim, M.; Na, H.; Park, S.C.; Jeon, Y.S.; Lee, J.H.; Yi, H.; et al. Introducing EzTaxon-e: A prokaryotic 16S rRNA gene sequence database with phylotypes that represent uncultured species. *Int. J. Syst. Evol. Microbiol.* **2012**, *62*, 716–721. [[CrossRef](#)] [[PubMed](#)]
31. Saitou, N.; Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* **1987**, *4*, 406–425. [[CrossRef](#)]
32. Kumar, S.; Stecher, G.; Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. *Mol. Biol. Evol.* **2016**, *33*, 1870–1874. [[CrossRef](#)]
33. Edgar, R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* **2004**, *32*, 1792–1797. [[CrossRef](#)]
34. Felsenstein, J. Evolutionary trees from DNA sequences: A maximum likelihood approach. *J. Mol. Evol.* **1981**, *17*, 368–376. [[CrossRef](#)]
35. Ayuso-Sacido, A.; Genilloud, O. New PCR primers for the screening of NRPS and PKS-I systems in Actinomycetes: Detection and distribution of these biosynthetic gene sequences in major taxonomic groups. *Microb. Ecol.* **2005**, *49*, 10–24. [[CrossRef](#)]
36. Schneemann, I.; Kajahn, I.; Ohlendorf, B.; Zinecker, H.; Erhard, A.; Nagel, K.; Wiese, J.; Imhoff, J.F. Mayamycin, a Cytotoxic Polyketide from a *Streptomyces* Strain Isolated from the Marine Sponge *Halichondria panicea*. *J. Nat. Prod.* **2010**, *73*, 1309–1312. [[CrossRef](#)] [[PubMed](#)]
37. Silber, J.; Ohlendorf, B.; Labes, A.; Erhard, A.; Imhoff, J.F. Calcarides A–E, antibacterial macrocyclic and linear polyesters from a calcarisporium strain. *Mar. Drugs* **2013**, *11*, 3309–3323. [[CrossRef](#)]
38. Buckingham, J. *Dictionary of Natural Products on DVD*, version 21:1; CRC Press Taylor and Francis Group: London, UK, 2012.

39. Chun, J.; Oren, A.; Ventosa, A.; Christensen, H.; Arahal, D.R.; da Costa, M.S.; Rooney, A.P.; Yi, H.; Xu, X.W.; De Meyer, S.; et al. Proposed minimal standards for the use of genome data for the taxonomy of prokaryotes. *Int. J. Syst. Evol. Microbiol.* **2018**, *68*, 461–466. [[CrossRef](#)]
40. Lindenbein, W. Über Einige Chemisch Interessante Aktinomycetenstämme Und Ihre Klassifizierung. *Arch. Mikrobiol.* **1952**, *17*, 361–383. [[CrossRef](#)]
41. De Querioz, V.M.; Albert, C.A. *Streptomyces iakyrus* nov. sp., produtor dos antibióticos Iaquirina I, II, III. *Rev. Inst. Antibiot. Univ. Recife* **1962**, *4*, 33–46.
42. Ryabova, I.D.; Preobrazhenskaya, T.P. *Problems of Classification of Actinomycetes-Antagonists*; Gauze, G.F., Preobrazhenskaya, T.P., Kudrina, E.S., Blinov, N.O., Ryabova, I.D., Sveshnikova, M.A., Eds.; Government Publishing House of Medical Literature: Medgiz, Moscow, Russia, 1957; pp. 1–398.
43. Gause, G.F.; Preobrazhenskaya, T.P.; Sveshnikova, M.A.; Terekhova, L.P.; Maximova, T.S. *A Guide for the Determination of Actinomycetes. Genera Streptomyces, Streptovercillium, and Chainia*; Nauka: Moscow, Russia, 1983.
44. Han, L.; Zhang, G.; Miao, G.; Zhang, X.; Feng, J. *Streptomyces kanasensis* sp. nov., an Antiviral Glycoprotein Producing Actinomycete Isolated from Forest Soil Around Kanas Lake of China. *Curr. Microbiol.* **2015**, *71*, 627–631. [[CrossRef](#)] [[PubMed](#)]
45. Okami, Y.; Umezawa, H. Production and isolation of a new antibiotic, kanamycin. *J. Antibiot.* **1957**, *10*, 181–189.
46. Goodfellow, M.; Williams, S.T.; Alderson, G. Transfer of *Kitasatoa purpurea* Matsuma and Hata to the genus *Streptomyces* as *Streptomyces purpurea* comb. nov. *Syst. Appl. Microbiol.* **1986**, *8*, 65–66. [[CrossRef](#)]
47. Onaka, H. Biosynthesis of heterocyclic antibiotics in Actinomycetes and an approach to synthesize the natural compounds. *Actinomycetologica* **2006**, *20*, 62–71. [[CrossRef](#)]
48. Sánchez, C.; Méndez, C.; Salas, J.A. Engineering biosynthetic pathways to generate antitumor indolocarbazole derivatives. *J. Ind. Microbiol. Biotechnol.* **2006**, *33*, 560–568. [[CrossRef](#)]
49. Bowers, K.J.; Mesbah, N.M.; Wiegel, J. Biodiversity of poly-extremophilic Bacteria: Does combining the extremes of high salt, alkaline pH and elevated temperature approach a physico-chemical boundary for life? *Saline Syst.* **2009**, *5*, 9. [[CrossRef](#)]
50. Dorador, C.; Vila, I.; Imhoff, J.F.; Witzel, K.-P. Cyanobacterial diversity in Salar de Huasco, a high altitude saline wetland in northern Chile: An example of geographical dispersion? *FEMS Microbiol. Ecol.* **2008**, *64*, 419–432. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).